Intensive efforts have been made to develop an effective therapy for Duchenne muscular dystrophy (DMD). Although myoblast transplantation has been found capable of transiently delivering dystrophin and improving the strength of the injected dystrophic muscle, this approach has been hindered by the immune rejection problems as well as the poor survival and limited spread of the injected cells. In the present study, we have investigated whether the careful selection of donor myoblasts and host muscle for the myosin heavy chain expression (MyHCs) plays a role in the success of myoblast transfer. Highly purified normal myoblasts derived from the m. soleus and m. gastrocnemius white of normal mice were transplanted into the m. soleus (containing 70% of type I fibers) and gastrocnemius white (100% of type II
Introduction
Duchenne muscular dystrophy (DMD) is a common Xlinked recessive muscular dystrophy caused by a deficiency of dystrophin, an important component of the plasma membrane cytoskeleton of muscle fibers. [1] [2] [3] [4] [5] Dystrophin deficiency leads to a continuous loss of muscle fibers with progressive muscle weakness and the death of patients in their third decade of life. Effective gene therapy for DMD will require the transfer of adequate copies of either the full-length dystrophin gene or dystrophin minigenes in affected muscle to restore adequate production of dystrophin for compensation of the weakness. [6] [7] [8] [9] [10] The transplantation of normal myoblasts into dystrophin-deficient muscle to create a reservoir of dystrophinproducing myoblasts capable of fusing with dystrophic myofibers has been studied extensively in both mdx mice (an animal model for DMD) and DMD patients. [11] [12] [13] [14] [15] [16] Although these studies showed transient restoration of dystrophin and increase of strength in dystrophic muscle, the limited success of myoblast transplantation has been related to immune rejection, poor survival and limited spread of injected myoblasts after transplantation. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Indeed, long-term persistence of dystrophin has been fibers) of dystrophin deficient mdx mice. At several timepoints after injection (10, 20 and 30 days) , the number of dystrophin-positive fibers was monitored and compared among the different groups. A significantly higher number and better persistence of dystrophin-positive myofibers were observed when the injected muscle and donor myoblasts expressed a similar MyHC in comparison with myoblast transfer between host muscle and donor myoblasts that were not matched for MyHC. These results suggest that careful matching between the injected myoblasts and injected muscle for the MyHC expression can improve the efficiency of myoblast-mediated gene transfer to skeletal muscle. Gene Therapy (2000) 7, 428-437.
observed in animals adequately immunosuppressed 31 and in immunodeficient mice. 16, 22, 23 Recently it has been found that the poor survival of the injected myoblasts is partially related to inflammatory reactions. 33 In an effort to bypass this limitation, myoblasts were engineered to express anti-inflammatory substances (IL-1Ra): these engineered myoblasts preserved their ability to fuse in the injected muscle in vivo and improved the survival of the injected myoblasts after implantation in comparison with non-engineered control myoblasts. 34 Although an improvement of cell survival can be achieved by blocking inflammation, a substantial loss of injected cells remains following myoblast transfer. 33, 34 We then investigated whether other factors were involved with the poor cell survival after transplantation.
It has been observed that only a discrete subpopulation of muscle-derived cells is capable of surviving after implantation and therefore participating in muscle regeneration. 35 We investigated whether the purification of muscle-derived cells could lead us to isolate this small proportion of cells highly capable of surviving after implantation in skeletal muscle. We have indeed observed that isolation of specific populations of musclederived cells can help in the development of approaches to circumvent the poor survival of injected myoblasts after transplantation. 34 Briefly, different populations of muscle-derived cells isolated from the mdx hindlimb muscles have been adenovirally transduced, and the early fate of the injected cells evaluated at different timepoints after injection (0.5, 12, 24, 48 h and 5 days). When the same number of muscle-derived cells at different purities (preplate No. 1 versus preplate No. 6) were injected into mature muscles, an 83% loss and 124% gain were observed in the transgene expression when compared with the non-injected transduced cells. This observation suggests that the isolation of specific populations of muscle-derived cells can overcome the rapid loss of the injected cells and may further improve the efficiency of the myoblast-mediated ex vivo gene transfer approach. 34 We have consequently observed that the cells displaying the best survival also lead to better gene transfer in comparison with the cells that die rapidly after transplantation. 34 In order to elucidate the mechanism by which the specific population of muscle-derived cells display a significant improvement in cell survival, we have investigated whether the specific population of muscle-derived cells has a differential ability to fuse with myofibers expressing different myosin heavy chain (MyHC) isoforms. We observed that the myoblast populations displaying good survival after injection were in fact capable of fusing both with fast and slow myofibers in contrast to myoblasts obtained from isolated single myofibers, which quickly die after injection and either fused only together or with host fast myofibers. 34 The inability of myoblasts obtained from isolated single myofibers to fuse with both types of myofibers may be involved in the differential survival of the injected myoblasts, since the injected muscle contains a mixture of the m. gastrocnemius (fast type) and soleus (slow type). The injected myoblasts that are less able to fuse with some specific types of host myofibers may likely display a poor survival at the injection site.
In this article, we report that the types of donor myoblasts and host muscles (slow and fast muscle) play a major determinant in myoblast transplantation. By using normal primary myoblasts derived from different types of muscles (slow or fast twitch muscles), we have been able to modify the efficiency of myoblast complementation in dystrophic muscle. In fact, higher efficiency of myoblast transfer as well as better persistence of dystrophin expression has been observed when the host muscles are carefully matched with the donor cells for the type of MyHC expression. This study will not only further our understanding of skeletal muscle regeneration, but also create new strategies to improve the efficiency of cell and gene therapy to deliver dystrophin in DMD muscles.
Results
The The composition of donor normal and host mdx muscles Immunochemical staining demonstrated a difference between the percentage of type I myofibers (the ratio of type I myofibers to total myofibers) in donor normal and host mdx soleus, being 44.1 ± 2.3 (n = 5) and 71.2 ± 3.4% (n = 5), respectively (not shown). However, the percentage of type I myofibers in tibialis anterior (TA), gastrocnemius mixed, and white muscles was not different between donor and host muscles. More than 99% of muscle fibers in TA were fast type. ATPase staining showed that TA contained type IIA, IIB and IIX fibers. The gastrocnemius white muscle contained 100% of fast muscle fibers, and ATPase staining revealed that 80% of the fibers were type IIB and the rest were type IIX (not shown). Figure 2a ). This suggests that purification of the muscle cells by the preplating technique improves the efficiency of myoblast transfer in mixed gastrocnemius muscle, despite the fact that these myoblast populations originated from different phenotypes, ie fast (tibialis anterior) and slow muscles (soleus).
Dystrophin expression in the m. soleus Highly purified primary myoblasts, containing more than 90% desmin-positive cells, derived from the m. soleus (Mbs) and gastrocnemius white (Mbf) of normal mice were transplanted to the m. soleus (s) of mdx mice. The transplantation of the same number of myoblasts derived from soleus (Mbs) showed a better gene complementation in the m. soleus (Mbs-s) than the myoblasts derived from gastrocnemius white muscle (Mbf-s) at 10 days after injection (Figure 3a-e) . Co-localization of the expression of dystrophin (Cy3) and slow myosin heavy chain (FITC) showed that the myoblasts derived from soleus (Mbs) fused with both host slow and fast myofibers ( Figure 3a , b, see arrows). However, the myoblasts from fast muscle (Mbf) fused together or with rare host fast myofibers, because the dystrophin-positive myofibers never co-localized with slow myosin heavy chain expressing myofibers (Figure 3c, d ). In the slow muscle injected by Mbf cells, the dystrophin-positive myofibers were detected only in a small area of the injected site, although a large area containing fluorescent latex microspheres (green beads) was detected ( Figure 3d ). 
Figure 1 Expression of dystrophin and myosin heavy chain isoforms in cell cultures. The muscle cells isolated from soleus (Sol), gastrocnemius white (GW), and tibialis anterior (TA) were tested for the expression of slow (a-c), fast (d-f) myosin heavy chain (MyHC) isoforms and dystrophin (g-i). All the cells were capable of differentiating into myotubes that were dystrophin (g-i) and fast MyHC (d-f) positive, but a variable extent of slow-MyHC staining was detected in the cultures obtained from different muscles (a-c, see text for details). Bar, 50 m in a-h and 40 m in i.
This result suggests that most of the injected cells died after transplantation into the muscle when they were not matched for the MyHCs. Consequently, the number of dystrophin-positive myofibers observed in the soleus muscles injected with myoblasts originating from slow muscles (Mbs) is significantly higher (*P Ͻ 0.05) than in the muscle injected with myoblasts originating from fast (Mbf) muscle (Figure 3e ).
Dystrophin expression in the m. gastrocnemius (white)
The transplantation of normal myoblasts originating from slow muscle (Mbs) also led to the formation of dystrophin-positive myofibers in the injected gastrocnemius (white) muscle (Mbs-f). These dystrophin-positive myofibers expressed fast MyHC (Figure 3f) . A poor correlation between the area of dystrophin-positive myofibers and the distribution of latex microspheres (Figure 3f , arrows) suggests that some of the injected cells died in the injected muscle. In contrast, the transplantation of myoblasts originating from fast muscle in the gastrocnemius white (Mbf-f) led to a higher number of dystrophin-positive myofibers than transplantation of a similar number of normal cells originating from slow muscle (Figure 3g, h ). All the dystrophin-positive myofibers found in the injected dystrophic muscle (Mbf-f) were found to be negative for slow myosin heavy chain.
Determination of persistence of dystrophin-positive fibers in the muscle injected with donor myoblasts expressing a similar MyHC Long-term survival of dystrophin-positive fibers was found in the gastrocnemius white muscle (fast) injected with normal myoblasts isolated from fast muscle ( Figure  4a -f). Many dystrophin-positive myofibers were found to persist in the injected muscle for at least 30 days after injection. At 20 days after injection (F-F20), 45.0% of the dystrophin-positive myofibers observed at 10 days after injection (F-F10) remained (1087.5 ± 260.5 on day 10 versus 489.3 ± 52.0 on day 20; n = 4 for each group). Moreover, no decrease in the number of dystrophin-positive myofibers was observed between 20 (F-F20) and 30 days (F-F30, 507.7 ± 158.5, n = 4) after injection. In fact, 46.7% of the dystrophin-positive myofibers observed at 10 days after injection remained at 1 month after transplantation.
Determination of persistence of dystrophin-positive fibers in injected muscle with donor myoblasts incompatible for MyHC expression The number of dystrophin-positive myofibers found in the white gastrocnemius muscle injected with normal myoblasts originating from soleus muscle at 10 days after injection (S-F10) rapidly declined at 20 (S-F20) and 30 days after injection (S-F30). At 30 days after injection 
Figure 2 Purification of muscle-derived cells improves the efficiency of myoblast transplantation. The transplantation of the same number of cells isolated from soleus (S) and tibialis anterior (T), obtained after the fourth preplate (T.#4; S.#4), leads to a higher number of dystrophin-positive myofibers (c, e) than the transplantation of cells obtained after the second preplate (T.#2; S.#2, b, d). A significant difference in the number of dystrophin-positive myofibers is observed. *P Ͻ 0.05 when PP#4 (S.#4, T.#4) is compared with PP#2 (S.#2, T.#2) (n = 4 for each group). Bar, 100 m in b-e.
( Figure 4k, l) , only 15.1% of dystrophin-positive myofibers from 10 days after injection (Figure 4g , h) were detected in the injected muscle. In fact, a major reduction in the number of transduced myofibers was found between 10 and 20 days (713.6 ± 308.2 versus 187.5 ± 57.8; n = 4 for each group), and between 20 and 30 days (187.5 ± 57.8 versus 108.0 ± 21.5; n = 4 for each group).
Discussion
Myoblast transplantation and gene therapy have been extensively used to deliver genes to skeletal muscle. Although both approaches were found capable of achieving gene delivery to skeletal muscle, the expression has been transient. The limitations related to myoblast transGene Therapy plantation reside in the poor survival of the injected cells, the immune rejection problems, and the low spreading of myoblasts in the transplanted muscle. Similarly, gene therapy to skeletal muscle has been hindered by the lack of transgene persistence related to cytotoxicity of viral vectors, immune rejection problems triggered by the transgene and viral proteins, and the inability to transduce mature myofibers efficiently. Development of new generations of viral vectors, including the triple mutant HSV-1 vector [36] [37] [38] [39] and the third generation adenovirus that lack all viral proteins, [40] [41] [42] [43] has helped to bypass the transient expression of the transgene. On the other hand, the development of new viral vectors, such as the adenoassociated virus, has helped to circumvent both the maturation-dependent viral transduction of mature myofibers 
The transplantation of myoblasts isolated from slow muscle into slow muscle (Mbs-s) is capable of fusing together to form dystrophin-positive small myofibers, or fusing with host myofibers expressing slow (arrow) and fast MyHC (arrowheads) myofibers (a, b). The transplantation of fast myoblasts into the slow muscle (Mbf-s) leads to formation of dystrophin-positive myofibers expressing exclusively fast MyHC (c, d arrow heads). The number of dystrophin-positive myofibers is significantly higher (*P Ͻ 0.05) when the transplanted cells matched the host muscle (Mbs-s) than when they did not (Mbf-s, e). The transplantation of myoblasts isolated from fast muscle (Mbf), however, is capable of fusing together and with host myofibers expressing dystrophin but not slow MyHC when injected into gastrocnemius white muscle (Mbf-f, g). The transplantation of myoblasts isolated from slow muscle (Mbs) into the white gastrocnemius muscle (Mbs-f, f) leads to the formation of myofibers expressing dystrophin (red fluorescence) but no slow MyHC (green fluorescence). The number of dystrophin-positive myofibers found in the white gastrocnemius muscle is higher when the injected cells are from fast muscle (Mbf-f) than from slow muscle (Mbs-f). The co-localization of fluorescent latex microspheres (FLMs green beads) with the dystrophin-positive myofibers suggests that the dystrophin-positive myofibers form by the fusion of the injected myoblasts and are not revertants (n = 4 for each group)
. Bar, 100 m.
and the transient expression of the delivered gene into skeletal muscle. [44] [45] [46] Although these new developments in gene therapy have improved the efficiency of gene transfer in skeletal muscle, the application of this technology for Duchenne muscular dystrophy is still extremely limited. The adenoassociated virus is incapable of carrying exogenous genes encompassing 5 Kba in length. In addition, the intramuscular injection of the new generation herpes simplex virus and adenovirus remains hindered by the inability to transduce mature myofibers. 47, 48 Although many approaches to improve viral transduction of mature myofibers are being investigated, 47, 48 it has recently been observed that the use of systemic delivery of viral vectors in conjunction with histamine-induced endothelial permeabilization can improve viral gene delivery in mature myofibers. 49 We have observed that myoblast-mediated ex vivo gene transfer can improve the efficiency of viral gene delivery in adult muscle when compared with direct injection of the viral particles. 50, 51 This improvement of viral gene transfer in mature myofibers using the ex vivo approach is obtained despite the fact that 95% of the injected cells die rapidly after injection. 17, 18, 24, [33] [34] [35] The poor survival of myoblasts can be significantly reduced by blocking inflammation using either anti-inflammatory substances, such as anti-LFA-1, 33 or myoblasts engineered to express anti-inflammatory agents, such as interleukin-1 receptor antagonist protein. 34 Although inflammation seems to play a major role in cell survival after injection, a substan- 
f). In contrast, the transplantation of myoblasts isolated from slow muscle into the white gastrocnemius muscle (S-F10, 20, 30) leads to the formation of dystrophin-positive myofibers at 10 days after injection (S-F10; g, h) that drastically decreases in number at 20 days (S-F20; i, j) and 30 days after injection (S-F30; k, l). The co-localization of fluorescent latex microspheres (FLMs green beads) with the dystrophin-positive myofibers suggests that the dystrophin-positive myofibers were formed by the fusion of the injected myoblasts and are not revertants. Bar, 50 m in a; 100 m in c, e, g, i, k; and 200 m in b, d, f, h, j, l.
Gene Therapy tial loss of the injected cells remains after adequate blockage of inflammatory reactions. 33, 34 Through the isolation of specific populations of muscle-derived cells, we can modulate the poor survival of the injected myoblasts. In fact, while some populations of muscle-derived cells died soon after injection, other populations of purified muscle-derived cells isolated from the same muscle all survived without blocking inflammation. 34, 35 These results suggest that the careful selection of muscle-derived cells can bypass the poor survival of the injected myoblast.
We have investigated the reason why this specific population of muscle-derived cells totally survives after implantation. It seems that the myoblast fusion in the host muscle is muscle fiber dependent. 34 The myoblasts isolated from fast single muscle fibers fused together or with host myofibers expressing the same phenotype. In contrast, myoblasts isolated from hindlimb mixed muscle fused with both fast and slow types of host myofibers. 34 The myoblasts incapable of fusing with host myofibers are consequently incapable of participating in muscle regeneration in vivo.
This study provides a broader observation on this question, testing transplantation of different populations of muscle-derived cells from normal fast or slow muscles into various types of dystrophic muscle. The soleus and white gastrocnemius muscles have been used as host and donor muscles for myoblast transplantation. We found, as previously reported, that the soleus muscle contains type I and IIA myofibers 52 and the white gastrocnemius muscle contains type IIB and IIX. The overall goal of this experiment is to investigate whether the careful matching of the injected myoblasts and the host muscle for the MyHCs expression acts as a major determinant of the success or failure of myoblast transfer. The salient features of the results presented in this report are as follows:
( . The result indicates that purification by preplating of the primary cultures isolated from either fast (tibialis anterior) or slow muscles (soleus) will lead to the isolation of myoblasts at the latter preplates that display a better myoblast transfer than the earlier preplates ( Figure 2) .
(2) The injection of purified muscle-derived cells originated from slow or fast muscle plays a role in the efficiency of myoblast transfer: We observed that the isolation of purified cells from slow (Mbs) or fast (Mbf) muscle leads to a differential myoblast transfer when injected in slow or fast host muscle. When the injected cells were isolated from normal soleus (slow) and injected into host dystrophic soleus muscle (Mbs-s), they fused together or with host slow myofibers, consequently leading to a high efficiency of myoblast transfer. Some of the injected cells also fused with host fast myofibers, which is not peculiar since the soleus also contained fast type myofibers.
When the injected cells originated from white gastrocnemius (fast) were injected into soleus muscle, they only fused together to form fast myofibers or with rare fast host myofibers within the soleus, but did not fuse with Gene Therapy host slow myofibers (Figure 3 ). The efficiency of myoblast transfer in soleus muscle is significantly higher when the myoblasts derived from the same source were injected (Mbs-s) instead of the same number of myoblasts derived from fast muscle (Mbf-s).
A larger number of dystrophin-positive myofibers which did not express slow MyHC were found in the host white gastrocnemius muscle injected with Mbf myoblasts (Mbf-f) than with the same number of soleusderived myoblasts (Mbs-f) (Figure 3f-h) . The results demonstrated that when the injected muscle is predominant in fast type, such as gastrocnemius white muscle, a better myoblast transfer was achieved by using Mbf instead of muscle-derived cells from slow muscle (Mbs). These results suggest that the success of transplantation of muscle-derived cells may be greatly improved by matching the expression of the MyHCs between the donor and host receiver muscle.
Although myoblasts derived from the m. soleus can differentiate into myotubes expressing fast MyHCs, they did not exhibit the same efficiency of gene complementation in host fast muscle (Mbs-f) as the myoblasts obtained from white gastrocnemius (Mbf-f). Since the dystrophin-positive myofibers detected in host fast muscle transplanted with Mbs (Mbs-f) did not express slow MyHC, these dystrophin-positive fibers were most likely formed by the fusion of the small proportion of fast type myoblasts that exist in soleus culture or with host fast myofibers. The findings suggest that myoblasts may have acquired an inheritable ability to fuse with host muscle fibers expressing the same phenotypes, instead of fusing with the host fibers expressing a different MyHC phenotype.
Our results also suggest that matching the donor myoblast with the host muscle for the MyHCs enhances the myoblast fusion with host myofibers and consequently enhances the efficiency of myoblast transfer. In fact, the ability of the same number of normal muscle-derived cells to lead to a good myoblast transplantation in muscle matched for the MyHCs versus the poor success of myoblast transfer in non-matched muscle suggests that myoblast fusion with the host myofibers is greatly improved by matching the injected cells and host muscle for the MyHCs.
(3) The careful matching of donor myoblasts and host muscle leads to a better persistence of dystrophin expression: The transplantation of fast myoblasts into white gastrocnemius muscle (Mbf-f) leads to the formation of a high number of dystrophin-positive myofibers that persists for up to 30 days after injection. In contrast, the transplantation of slow myoblasts in the injected white gastrocnemius (Mbs-f) leads to the formation of dystrophin-positive myofibers at 10 days after injection that quickly declines at 20 and 30 days after injection. The results provide more evidence that the careful selection of donor cells and host muscle leads to better persistence of dystrophin expression. The gradual disappearence of dystrophin-positive fibers is probably related to immune responses. Indeed, similar allograft transplantation of normal myoblasts into mdx mice has led to a transient expression of dystrophin due to immune rejection problems. 53 It is interesting that the persistence of dystrophinpositive cells in the MyHCs matched for donor and receiver, although the same incompatibility exists. The mechanism by which the matching of injected myoblasts with the host muscle for the MyHCs can allow a longer persistence of the transgene is unclear and under investigation. The ability of injected cells to fuse with host fibers at a higher efficiency in the MyHC matched donor/host muscle may be involved in this phenomenon. We are investigating whether the inability of the injected cells to fuse with host mature myofibers, which results in fusing together into small myotubes, leads to a transient expression of dystrophin expression in the injected muscle.
(4) Donor myoblast versus receiver host muscle: Taken together, these observations suggest that myoblasts isolated from soleus muscle are better donor cells than cells isolated from white gastrocnemius muscle, since the soleus-derived myoblasts express both type of MyHCs and have the ability to fuse with both types of host myofibers. On the other hand, the white gastrocnemius is a superior host muscle than soleus in terms of the number of dystrophin-positive myofibers found following myoblast transfer, because soleus (Mbs-f) and white gastrocnemius-derived myoblasts (Mbf-f) can lead to a good myoblast transfer in the fast muscle at 10 days after injection. Although soleus-derived myoblasts (Mbs) are better donor cells than gastrocnemius-derived myoblasts (Mbf) according to their fusion with both host slow and fast myofibers, injection of the Mbs myoblasts into fast muscle (Mbs-f) leads only to transient expression of part of the dystrophin-positive myofibers. This observation suggests that the myotubes formed by the fusion of donor-derived myoblasts in the injected muscle leads only to transient expression of the dystrophin. In contrast, the injection of fast myoblasts into white gastrocnemius muscle (Mbf-f) leads to the fusion of the injected myoblasts with host mature myofibers and, consequently, to better persistence of the dystrophin-positive myofibers.
In summary, we have demonstrated in this article that the success of myoblast transplantation can either be significantly improved or reduced by injecting the musclederived cells in host muscle displaying similar or different MyHCs expression. Consequently, these results suggest that careful matching of the injected cells with the host receiver muscle lead to better myoblast transfer and longer persistence of dystrophin expression in the injected dystrophic muscle. Furthermore, these data may shed some light on the overall failure of the clinical trial of myoblast transplantation in DMD patients, and create new strategies to achieve efficient cell and gene therapy to skeletal muscle.
Materials and methods

Preparation of satellite cells
The purification of satellite cells was performed using a previously described protocol. 34, 54 The m. soleus, gastrocnemius (white), and tibialis anterior (TA) were removed from normal mice (C-57 BL/6J+/+) at 4-5 weeks of age, and the connective tissue was dissected. The remaining muscle mass was minced into a coarse slurry using razor blades. Cells were enzymatically dissociated by the addition of 0.2% collagenase-type XI (C-9407; Sigma, St Louis, MO, USA) for 1 h at 37°C, 2.4 units/ml of dispase (Gibco-BRL; grade II) for 45 min, and 0.1% trypsin (Gibco-BRL, Grand Island, NY, USA) for 30 min. The Gene Therapy experiment II, high purity Mbs and Mbf cells were injected into the m. soleus (slow) or gastrocnemius white (fast). At different time-points after injection (10, 20 and 30 days), the animals were killed and the injected muscle frozen in 2-methylbutane pre-cooled in liquid nitrogen. The muscles were then cryostat sectioned and assayed for dystrophin and MyHC isoforms by immunohiostochemistry.
Immunochemistry on muscle cells in vitro
Desmin staining: The muscle-derived cells were fixed with 100% methanol at −20°C for 2 min and rinsed in phosphate-buffered saline (PBS, pH 7.4). All further incubations were carried out at room temperature, and all rinses and dilution were performed with a blocking solution consisting of 2.5% house serum in PBS. An initial blocking step was performed with 5% house serum for 30 min, and the cells were incubated with a rabbit antibody to desmin (D-8281, Sigma) for 1 h at a dilution 1:200. After three rinses in PBS, the cells were incubated with a secondary antibody, anti-rabbit conjugated to Cy3 immunofluorescence (1:200, C-2181; Sigma). The immunostaining was then visualized by a fluorescent microscopy (Eclipse E800, Nikon, Melville, NY, USA), and the percentage of myogenic cells determined as the ratio of desmin-positive cells to the total number of cells in five randomly chosen fields at a magnification of 200 ×.
MyHCs and dystrophin staining: Two monoclonal antibodies specific for myosin heavy chain isoforms were used in this study: anti-slow myosin heavy chain (M 8421; Sigma) reacted to adult skeletal muscle slow MyHC; anti-fast (M 4276; Sigma) reacted to all sub-types of adult fast MyHCs. The staining was performed using the indirect immunoperoxidase technique. The cells were fixed with cold methanol for 2 min. Following three rinses, the cells were preincubated with 5% horse serum in PBS (pH 7.4) for 1 h at room temperature and then incubated overnight in a humid chamber with primary antibodies diluted 1:500 (anti-slow), 1:400 (anti-fast), respectively, in PBS with 2.5% horse serum. After three rinses in PBS, the cells were incubated with sheep anti-mouse antibodies conjugated with horseradish peroxidase (A 7282, Sigma), diluted 1:100 in PBS for 90 min. Following three rinses in PBS, the stainings were revealed by incubation with 1 mg/ml diaminobenzidine (D-4168; Sigma) containing 0.03% hydrogen peroxidase. Reaction was performed in the dark for 10 min at room temperature and stopped by repeated rinses in PBS. For dystrophin staining the muscle cells were fixed with cold methanol (100%) for 1 min, rinsed in PBS, and incubated with an anti-dystrophin antibody (rabbit 6-10, 1/1000) overnight at room temperature. Following several rinses in PBS, the cells were incubated with an anti-rabbit conjugated to Cy3 (1/200) for 2 h.
Histochemical and MyHC staining for muscle fiber types Myofibrillar ATPase staining and immunohistochemical staining (anti-slow MyHC) were used to determine the muscle fiber types of host and donor muscles. Serial sections of 10 m thickness of the muscle were prepared using a cryostat.
Anti-slow MyHC staining: Staining was performed using indirect immunoperoxidase techniques. The sections were fixed in acetone at −20°C for 2 min. The next steps were the same protocol as described above (for MyHCs staining in vitro).
Myofibrillar ATPase staining:
The subtypes of fast muscles were determined by using the myosin ATPase histochemical method. [55] [56] [57] In these stainings, type IIB myofibers stained intermediate, and types IIA and IIX fibers stained dark after alkaline pretreatment (pH 9.40). IIX fibers stained dark, IIB stained intermediate, and IIA stained very light after preincubations at pH 4.45.
Co-localization of dystrophin and slow MyHC isoform by immunofluorescence Ten m cryostat sections were collected on glass slides and fixed in acetone at −20°C for 2 min. Following three rinses, the sections were preincubated for 1 h at room temperature with 5% horse serum in PBS (pH 7.4) and then incubated overnight in a humid chamber with antislow myosin heavy chain antibodies (M 8421; Sigma), diluted 1:500 in PBS containing 2.5% horse serum. Following three rinses in PBS, the sections were incubated with anti-mouse IgG, conjugated with FITC (1:100) for 90 min. After three rinses in PBS, the sections were incubated with a rabbit anti-dystrophin (1:1000, 6-10 antibody; a gift from Dr LM Kunkel, The Children's Hospital, Boston, MA, USA) for 2 h, and then incubated with antirabbit IgG, conjugated with Cy3 (1:200) for 90 min.
Negative control staining, with pre-immune sera or 2.5% horse serum substituted for the primary or secondary antibodies, was also performed. Sections were mounted in Gel/Mount (M01; Biomeda, Foster City, CA, USA) and observed under light and fluorescent microscopy (Nikon Optiphot Microscope).
Statistics
For the quantification of dystrophin-positive myofibers, the muscle sections with the highest number of dystrophin-positive myofibers were selected and counted for each muscle. Four muscle samples were used in each group. The mean ± standard deviation was monitored and compared among the different groups. Comparisons between the different groups were performed using the unpaired Student's t test. A level of P Ͻ 0.05 was considered significant for the differences between mean values (*).
